Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03383575
Title Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Azacitidine + Enasidenib

Enasidenib

Age Groups: adult | senior | child
Covered Countries USA

Additional content available in CKB BOOST